1.52
price down icon7.32%   -0.12
pre-market  Vorhandelsmarkt:  1.53   0.01   +0.66%
loading

Ocugen Inc Aktie (OCGN) Neueste Nachrichten

pulisher
01:37 AM

Ocugen at H.C. Wainwright: Progress in Gene Therapy for Blindness By Investing.com - Investing.com Canada

01:37 AM
pulisher
01:09 AM

Ocugen at H.C. Wainwright: Progress in Gene Therapy for Blindness - Investing.com

01:09 AM
pulisher
Sep 25, 2025

Ocugen, Inc. Hits New 52-Week High at $1.78, Marking Significant Milestone - Markets Mojo

Sep 25, 2025
pulisher
Sep 24, 2025

Ocugen (NASDAQ:OCGN) Reaches New 52-Week HighTime to Buy? - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Ocugen Shares Surge as Strategic Shift Renews Investor Confidence - AD HOC NEWS

Sep 24, 2025
pulisher
Sep 23, 2025

200,100 Shares in Ocugen, Inc. $OCGN Acquired by Procyon Advisors LLC - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ocugen's (OCGN) Buy Rating Reaffirmed at Chardan Capital - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN) - Seeking Alpha

Sep 23, 2025
pulisher
Sep 23, 2025

Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN

Sep 23, 2025
pulisher
Sep 22, 2025

Why Ocugen Stock Zoomed 12% Higher Today - MSN

Sep 22, 2025
pulisher
Sep 21, 2025

Why Ocugen (OCGN) Is Up 25.2% After Securing Korean Rights for Gene Therapy OCU400 - simplywall.st

Sep 21, 2025
pulisher
Sep 20, 2025

Valuation Update: Can Ocugen Inc. weather a recessionJuly 2025 Analyst Calls & Precise Buy Zone Identification - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

How does Ocugen Inc. score in quality rankingsEarnings Summary Report & Weekly Sector Rotation Insights - khodrobank.com

Sep 20, 2025
pulisher
Sep 20, 2025

Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛

Sep 20, 2025
pulisher
Sep 20, 2025

Nasdaq Moves: Is Ocugen Inc a momentum stock2025 Earnings Surprises & Reliable Intraday Trade Plans - خودرو بانک

Sep 20, 2025
pulisher
Sep 19, 2025

Ocugen gets EU approval for Prolia and Xgeva biosimilars (OGN:NYSE) - Seeking Alpha

Sep 19, 2025
pulisher
Sep 19, 2025

Ocugen (OCGN) Rating and Price Target Maintained by Chardan Capi - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

Aug PreEarnings: Whats the MACD signal for Ocugen Inc2025 Stock Rankings & AI Forecast Swing Trade Picks - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Ocugen Faces Merger Termination with Carisma Therapeutics - TipRanks

Sep 19, 2025
pulisher
Sep 18, 2025

Malvern-Based Ocugen Secures Multimillion Dollar Licensing Deal with Korean Pharma Giant - VISTA.Today

Sep 18, 2025
pulisher
Sep 18, 2025

Ocugen merger agreement with Carisma terminated due to funding shortfall By Investing.com - Investing.com Australia

Sep 18, 2025
pulisher
Sep 18, 2025

Ocugen Enters Subscription Agreement with Carisma Therapeutics - MSN

Sep 18, 2025
pulisher
Sep 18, 2025

Ocugen merger agreement with Carisma terminated due to funding shortfall - Investing.com

Sep 18, 2025
pulisher
Sep 18, 2025

Analyst Upgrade: Is Ocugen Inc. stock a smart retirement pickJuly 2025 Action & Accurate Buy Signal Alerts - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Ocugen Inc says on Sept 16, carisma terminates merger agreement with Ocugen - MarketScreener

Sep 18, 2025
pulisher
Sep 18, 2025

Carisma's lifeline dissipates as reverse merger plans fall through, Moderna cuts ties - Fierce Biotech

Sep 18, 2025
pulisher
Sep 18, 2025

Ocugen (OCGN): Evaluating Valuation Following Exclusive Korean Licensing Deal for Gene Therapy OCU400 - Yahoo Finance

Sep 18, 2025
pulisher
Sep 18, 2025

Highs Report: Is MSCI Inc. stock a good pick for beginnersJuly 2025 Opening Moves & Fast Momentum Stock Entry Tips - خودرو بانک

Sep 18, 2025
pulisher
Sep 17, 2025

Aug Movers: Is Ocugen Inc a cyclical or defensive stockMarket Performance Report & Safe Entry Point Identification - خودرو بانک

Sep 17, 2025
pulisher
Sep 17, 2025

Analysis Recap: Is Ocugen Inc. forming bullish engulfing patternsMarket Sentiment Report & Weekly High Potential Stock Alerts - خودرو بانک

Sep 17, 2025
pulisher
Sep 17, 2025

Setup Watch: Can Ocugen Inc be recession proofStop Loss & Precise Buy Zone Identification - خودرو بانک

Sep 17, 2025
pulisher
Sep 17, 2025

Panic Selling: What is the next catalyst for Ocugen IncWeekly Market Report & High Conviction Investment Ideas - خودرو بانک

Sep 17, 2025
pulisher
Sep 17, 2025

Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN

Sep 17, 2025
pulisher
Sep 16, 2025

Weekly Recap: How cyclical is Comtech Telecommunications Corps revenue streamFed Meeting & AI Powered Buy/Sell Recommendations - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Ocugen Signs Exclusive License Agreement with Kwangdong - TipRanks

Sep 16, 2025
pulisher
Sep 16, 2025

Gains Recap: What is the next catalyst for Mattel IncDay Trade & Reliable Price Action Trade Plans - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Ocugen, Kwangdong complete licensing agreement for OCU400 gene therapy in Korea - Modern Retina

Sep 16, 2025
pulisher
Sep 16, 2025

Why Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to Kwangdong - Yahoo Finance

Sep 16, 2025
pulisher
Sep 15, 2025

Ideas Watch: Is Ocugen Inc undervalued by DCF analysisWeekly Volume Report & Expert Curated Trade Setup Alerts - khodrobank.com

Sep 15, 2025
pulisher
Sep 15, 2025

Published on: 2025-09-16 04:47:37 - khodrobank.com

Sep 15, 2025
pulisher
Sep 15, 2025

Big Money Moves: Is Ocugen Inc showing insider buyingQuarterly Performance Summary & Weekly Momentum Stock Picks - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen (OCGN) Stock Rises on South Korea Licensing Deal - GuruFocus

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen Inc. stock rises Monday, outperforms market - AllSides

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen Shares Are Trading Higher Monday: What's Going On? - Benzinga

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen shares soar on gene therapy deal with Korean pharma giant - The Business Journals

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen and Kwangdong complete licensing agreement for OCU400 gene therapy in Korea - Ophthalmology Times

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen (OCGN) Secures Licensing Deal with Kwangdong for Gene Therapy in Korea - GuruFocus

Sep 15, 2025
pulisher
Sep 15, 2025

Ocugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 Million - Quiver Quantitative

Sep 15, 2025
$34.90
price down icon 2.43%
$81.66
price down icon 2.97%
$28.84
price down icon 2.07%
$98.08
price down icon 1.67%
$135.59
price down icon 3.84%
biotechnology ONC
$328.71
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):